🦊/Investors

Seroba Life Sciences β€” Full Portfolio

35 tracked investments Β· listed companies and verified rows first

Locilociorthopaedics.comβœ“ verified

Loci Orthopaedics develops extremity orthopaedic technologies, including its InDx device for the thumb base joint, using evidence-based design to address unmet clinical needs.

HealthtechMedical DevicesGalway, IE

Brendan Boland(Co-founder & Executive Chairperson)Gerry(Co-founder)Barry(CEO)Paul(Finance Leader)John(VP Technical Operations)

Co-investorsJohnson & Johnson Innovation – JJDCLaunch Capital

Palliarepalliare.comin𝕏Series A Β· Jun 2021 Β· $8Mβœ“ verified

Palliare develops medical devices for minimally invasive gastrointestinal procedures, including laparoscopy and endoscopy solutions.

HardwareHealthtechMedical DevicesOceanside, IE

John O'Dea(CEO)in

Co-investorsWestern Development Commission

Sibyllasibyllabiotech.itin𝕏Series A Β· Oct 2022 Β· $23Mβœ“ verified

Sibylla Biotech develops PPI-FIT, a drug discovery technology that uses quantum physics and mathematical modeling to characterize protein folding pathways at atomic resolution.

AI & Machine LearningBiotechDeep TechTrento, IT

Emiliano Biasini(Co-founder)inPietro Faccioli(Co-founder)inGiovanni Spagnolli(Co-founder, CTO)inMaria Letizia Barreca(Co-founder)inGraziano Lolli(Co-founder)

Co-investors3B Future Health FundCDP Venture CapitalV-Bio VenturesVertis SGRVI PartnersClaris Ventures+1 more

Alveus Therapeuticsalveustx.cominDec 2025

Alveus Therapeutics develops next-generation metabolic and obesity therapies, including its lead asset ALV-100 (in Phase 2) and a preclinical amylin pipeline of peptides, oral small molecules, and novel formats aimed at sustainable weight loss with better tolerability.

BiotechHealthtechLongevityPhiladelphia, US

Raj Kannan(Executive Officer, Director)

BoardClaudio Nessi(Director)inIvan Gergel(Director)inJan Van de Bossche(Director)inGarrett Ingram(Director)Gregory Parekh(Director)

Co-investorsAndera PartnersAvego BioScience CapitalGlobal BioAccess FundJeito CapitalNew Rhein Healthcare Investors, LLCAgent Capital+2 more

Artica Therapeuticsartica-tx.cominSeed Β· Nov 2023 Β· $13M

Artica Therapeutics develops orally bioavailable small molecule inhibitors that use covalent chemistry to achieve antibody-like efficacy, positioned as an "antibody-in-a-pill" approach.

BiotechDeep TechHealthtech

Tjeerd Barf(Co-founder & CEO)inArwin Ridder(Co-founder & COO)inAd IJzerman(Co-founder & SAB Chair)inJason(Chief Scientific Officer)in

Co-investorsBioGeneration VenturesThuja CapitalBGV

Atlantic Therapeuticscalderamedical.com

Caldera Medical develops surgical solutions for women's health conditions including stress urinary incontinence, pelvic organ prolapse, polyps, and fibroids.

FemTechHealthtechMedical Devices

Co-investorsAndera PartnersEarlybird Venture Capital

Azafarosazafaros.com

Azafaros is a clinical-stage biopharmaceutical company developing small-molecule therapies for severe rare genetic metabolic disorders, including GM1/GM2 gangliosidoses, Niemann-Pick type C disease, and other conditions.

BiotechDeep TechHealthtechMedical DevicesLeiden, NL

Hans Aerts(Professor)Hermen Overkleeft(Professor)Stan van Boeckel(Professor)

Co-investorsBioMedPartnersForbionJeito CapitalBioGeneration VenturesPictet Group

Coave Therapeuticscoavetx.comin

Coave Therapeutics develops targeted gene therapy vectors using its proprietary ALIGATER platform to deliver therapeutic genes to specific tissues with improved safety and precision.

BiotechDeep TechHealthtechMedical DevicesParis, FR

Co-investorsFund+Kurma PartnersV-Bio VenturesBpifranceInvusNovo Holdings+1 more

Complement Therapeuticscomplementtx.comApr 2023

Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies for complement-mediated diseases, with a lead AAV-based candidate (CTx001) for Geographic Atrophy secondary to Age-related Macular Degeneration.

BiotechDigital HealthHealthtechMedical DevicesMunich, DE

Rafiq Hasan(CEO and Managing Director)inMuhammad Ali Memon(Chief Medical Officer)in

Co-investorsCambridge Innovation CapitalHadean VenturesBGVBioGeneration VenturesForbionGimv+1 more

Deciphexdeciphex.comin𝕏Series B Β· Jan 2023 Β· $4M

Deciphex develops AI-powered platforms to enhance pathology efficiency, including digital image analysis, clinical trial support, and a global network of subspecialty pathologists.

AI & Machine LearningDigital HealthHealthtechMedical Devices

Co-investorsAct Venture CapitalACT Venture CapitalClaret Capital PartnersMolten Ventures

Endotronixendotronix.comin𝕏Mar 2014

Endotronix develops the Cordella PA Sensor and Heart Failure System, an FDA-approved implantable pulmonary artery pressure sensor and remote monitoring platform for managing patients with NYHA class III heart failure.

Digital HealthHealthtechMedical DevicesWoodridge, US

Harry Rowland(Executive Officer, Director)inAnthony I Nunez(Executive Officer, Director)inAnthony A. Nunez(Executive Officer, Director)inAnthony Nunez(Founder)in

BoardJonathan Jonas(Director)Raymond S. Barrett, Jr.(Director)

Co-investorsBioventures InvestorsJumpstart VenturesLumira VenturesOSF VenturesSV Health InvestorsLSP (Life Sciences Partners)

Fusion Pharmaceuticalsfusionpharma.comin𝕏Series A Β· Sep 2017 Β· $21M

Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells.

BiotechHealthtech

Co-investorsFACIT (Fight Against Cancer Innovation Trust)HealthCapLumira VenturesVenture OntarioYsios CapitalAdams Street Partners+2 more

Labcytebeckman.frDec 2016

BiotechSunnyvale, US

Richard Ellson(Executive Officer, Director)Tammy Cameron(Executive Officer)Mark Fischer-Colbrie(Executive Officer, Director)

BoardJoseph Smith(Director)Sandra Panem(Director)Joe Keegan(Director)

Co-investorsGE VenturesJP Morgan Chase

Medtechserobavc.comin

Seroba Ventures is an investment firm focused on bringing breakthrough healthcare solutions to market and addressing unmet patient needs in the global healthcare environment.

BiotechHealthtechMedical Devices

Jeanne Bolger(Venture Partner)

Perfuzeperfuze.cominSeries A Β· Feb 2022 Β· $26M

Perfuze develops medical devices for the treatment of acute ischemic stroke, focused on addressing unmet clinical needs in mechanical thrombectomy.

Deep TechHealthtechMedical DevicesGalway City, IE

Wayne Allen(Co-Founder, CEO, Director)inLiam Mullins(CTO and Co-founder)in

Co-investorsSV Health InvestorsEnterprise IrelandEQT Life Sciences

Precision Bioticsprecisionbiotics.iein𝕏

PrecisionBiotics develops food supplements containing specific bacterial strains aimed at supporting gut health and the microbiome for consumers and clinicians, alongside educational resources on gut health.

BiotechConsumerHealthtechWellness & Fitness

Prexton Therapeuticsprextontherapeutics.cominSeries B Β· Feb 2017 Β· $31Macquired by Lundbeck

Prexton Therapeutics was a biopharmaceutical company developing novel therapies for Parkinson's disease, including its lead mGluR4 modulator candidate foliglurax.

BiotechHealthtechMedical DevicesCopenhagen, DK

Co-investorsCardinal PartnersM VenturesSunstone CapitalYsios CapitalForbion

Quantaquantadt.cominNov 2019

Quanta develops the Quanta Dialysis System, a compact, modular hemodialysis machine designed for flexible kidney care in acute and chronic facilities.

HardwareHealthtechMedical DevicesBurbank, US

ERIC RICE(Executive Officer)JEFFREY DOIRON(Executive Officer)BLAKE GILETTE(Executive Officer)KIRK WESTWOOD(Executive Officer)

Co-investorsAccelComma Capital

Ryme Medicalrymemedical.com

Ryme Medical develops a catheter-based therapy to treat chronic obstructive pulmonary disease (COPD) by reducing airway inflammation and improving patient outcomes.

BiotechHealthtechMedical DevicesMountain View, US

Co-investorsEpidarex Capital

ShiraTronicsshiratronics.cominSep 2024

ShiraTronics is a medical device company developing an implantable device to treat chronic migraine disease.

BiotechHardwareHealthtechMedical DevicesBrooklyn Park, US

Robert Binney(Executive Officer, Director)

BoardJoyce Erony(Director)inZack Scott(Director)inBrad Vale(Director)inCasey Tansey(Director)Mudit Jain(Executive Officer, Director)in

Co-investorsAmzak HealthAPERTURE Venture PartnersBreakout VenturesGlobal BioAccess FundNorwest Venture PartnersOSF Ventures+3 more

Shorla Oncologyshorlaoncology.comin𝕏Oct 2023 Β· $35M

Shorla Oncology develops pharmaceutical products to address unmet needs in oncology.

BiotechHealthtechMedical DevicesDublin, IE

Sharon Cunningham(CEO & Co-Founder)inOrlaith Ryan(CTO & Co-Founder)in

Co-investorsKurma PartnersEnterprise Ireland

Storm Therapeuticsstormtherapeutics.comin𝕏Series A Β· May 2019 Β· $18M

STORM Therapeutics is a clinical-stage biotechnology company developing small molecule drugs that target RNA modifying enzymes to reprogram cells through RNA biology.

BiotechHealthtechMedical Devices

Co-investorsCambridge Innovation CapitalFast Track InitiativeM VenturesPfizer Venture InvestmentsTaiho Ventures, LLCUTokyo Innovation Platform Co. Ltd.+1 more

Veryanveryanmed.comin𝕏

Veryan Medical develops the BioMimics 3D Vascular Stent System, a three-dimensional nitinol stent designed around swirling blood flow mechanics to treat vascular disease.

HardwareHealthtechMedical DevicesLondon, DE

Vico Therapeuticsvicotx.com

Vico Therapeutics develops targeted genetic medicines for neurological disorders, with a focus on antisense oligonucleotide therapies designed to address the underlying genetic causes of diseases like Huntington's disease and spinocerebellar ataxias.

AI & Machine LearningBiotechDeep TechHealthtechMedical Devices

Luc Dochez(Chair and Founder)inJosh Mandel-Brehm(Co-Founder)in

Co-investorsDroia VenturesKurma PartnersPureos BioventuresEQT Life SciencesEurazeoIdinvest Partners+1 more

Other

Tracked investments with no reachable website or further public details β€” typically companies that wound down, renamed, or were absorbed.

Agi TherapeuticsApica CardiovascularCovagen AGHeart MetabolicsINNOVO by Atlantic TherapeuticsMedLumicsNovateNovate MedicalPQ BypassShorla PharmaXention

Rows marked β€œSEC filing” are inferred from directors named on the company's SEC Form D β€” public regulatory data, not a portfolio list published by the firm.